Eleven Biotherapeutics
Eleven Biotherapeutics
Eleven Biotherapeutics

Investor Relations

Focused on discovery and development of innovative ocular therapeutics using our proprietary protein engineering platform to treat patients suffering from eye diseases.

We create a new breed of potent and selective ophthalmic proteins. Eleven is creating a pipeline of engineered protein drugs for ocular diseases that are rationally designed for improved biological and drug-like properties.

  • Our differentiated ophthalmic protein products are designed for therapeutic impact in the ocular space. Eleven has a proprietary pipeline of product candidates for the treatment of ocular disease. Our products are engineered to treat both front-of-the-eye and back-of-the-eye diseases in new and effective ways.
  • Our technology enables innovative protein therapeutics. Eleven's proprietary protein engineering technology opens the potential to modulate key molecular targets responsible for the initiation or maintenance of an ocular disease.
  • EBI-005, Eleven's lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in clinical development as one of the first topically administered proteins for the treatment of inflammatory diseases at the surface of the eye, such as dry eye disease (DED) and allergic conjunctivitis (AC).
  • EBI-031, Eleven’s most advanced preclinical candidate, is a novel inhibitor of IL-6, for the treatment of diabetic macular edema.
NASDAQ: EBIO
Price:
3.00
Change:
- 0.10
Day High:
3.18
Day Low:
2.92
Volume:
430,400
4:00 PM ET on May 22, 2015
Delayed at least 20 minutes.
Media Contact:
Gina Nugent
The Yates Network
617-460-3579